Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History DNLI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics DNLI

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Denali Therapeutics Inc

DNLI
Current price
14.00 USD -0.53 USD (-3.65%)
Last closed 14.53 USD
ISIN US24823R1059
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 2 033 863 936 USD
Yield for 12 month -40.50 %
1Y
3Y
5Y
10Y
15Y
DNLI
21.11.2021 - 28.11.2021

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California. Address: 161 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

32.19 USD

P/E Ratio

Dividend Yield

Financials DNLI

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures DNLI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

Last Year

+330 531 000 USD

Current Quarter

Last Quarter

Current Year

Last Year

+313 805 000 USD

Current Quarter

Last Quarter

EBITDA -513 951 008 USD
Operating Margin TTM
Price to Earnings
Return On Assets TTM -22.58 %
PEG Ratio
Return On Equity TTM -35.21 %
Wall Street Target Price 32.19 USD
Revenue TTM
Book Value 7.73 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -100.00 %
Dividend Yield
Gross Profit TTM -395 235 008 USD
Earnings per share -2.67 USD
Diluted Eps TTM -2.67 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation DNLI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 2 843.16
Price Sales TTM 3 643.65
Enterprise Value EBITDA -8.66
Price Book MRQ 3.21

Technical Indicators DNLI

For 52 Weeks

10.57 USD 33.33 USD
50 Day MA 14.26 USD
Shares Short Prior Month 11 947 808
200 Day MA 19.47 USD
Short Ratio 7.92
Shares Short 12 457 321
Short Percent 9.21 %